{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:13:03Z","timestamp":1785521583930,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced biliary tract carcinoma (aBTC) comes with poor prognosis. Gemcitabine with oxaliplatin (GemOx) has emerged as a pragmatic alternative to gemcitabine with cisplatin and has been a preferred first line palliative option at many centres around the world. The evidence on second line chemotherapy following treatment failure of GemOx is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multicentre cohort study in the Southeast healthcare region of Sweden, covering nine years (2011\u20132020) and three hospitals, was conducted. All patients with aBTC who had received first line GemOx and any second line treatment thereafter were included. Treatment patterns and clinicopathological prognostic parameters were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a cohort of 121 patients with aBTC who had received GemOx in the first line setting, 57 (47%) had proceeded to any type of second line systemic therapy and were included in this study. The most used regimen was capecitabine single agent in 37 (64.9%) patients followed by intravenous 5-FU (9, 15.8%). Median overall survival (OS) in the total cohort was 4.1 months (95% CI 3.2-5.0). Six- and twelve-month survival rates were 35.6% and 18.6%. Median time to treatment failure (TTF) was 1.8 months (95% CI 1.5\u20132.2). Performance status (PS) 2, according to Eastern Cooperative Oncology Group (ECOG), was an independent predictor for poor OS and TTF. Progression free survival (PFS) of &lt;\u20096 months during first line treatment and extrahepatic localisation were independent predictors for poor OS. A nomogram was established using ECOG PS, 1st line PFS and primary tumour site. An exploratory prognostic model showed that patients with high total score in the nomogram had OS of 2.9 months compared to 4.3 months in patients with intermediate score and 13.1 months in patients with low score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with aBTC receiving second line chemotherapy following first line GemOx have very dismal prognosis. PS 0\u20131, first line PFS\u2009\u2265\u20096 months and intrahepatic disease localisation indicate better prognosis. These data highlight the need for improved and personalised treatment strategies in refractory aBTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16009-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:07:11Z","timestamp":1776413231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence on second line chemotherapy in advanced biliary tract carcinoma refractory to gemcitabine and oxaliplatin (GemOx)"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9335-1807","authenticated-orcid":false,"given":"Hanna","family":"Lagenfelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-1410","authenticated-orcid":false,"given":"Hakon","family":"Blomstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gr\u00e4nsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-0278","authenticated-orcid":false,"given":"Nils O","family":"Elander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"16009_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.SLA.0000251366.62632.D3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755\u201362. https:\/\/doi.org\/10.1097\/01.SLA.0000251366.62632.D3.","journal-title":"Ann Surg"},{"key":"16009_CR2","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28\u201337. https:\/\/doi.org\/10.1093\/annonc\/mdw324.","journal-title":"Ann Oncol"},{"key":"16009_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMOA0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMOA0908721.","journal-title":"N Engl J Med"},{"key":"16009_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet (London England)"},{"key":"16009_CR5","doi-asserted-by":"publisher","unstructured":"Oh D-Y, Ruth A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1. https:\/\/doi.org\/10.1056\/EVIDOA2200015.","DOI":"10.1056\/EVIDOA2200015"},{"key":"16009_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/CAM4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, et al. Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014;3:1502\u201311. https:\/\/doi.org\/10.1002\/CAM4.299.","journal-title":"Cancer Med"},{"key":"16009_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","volume":"123","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kalyan Mohanti B, Pal Chaudhary S, Sreenivas V, Kumar Sahoo R, Kumar Shukla N, et al. Modified gemcitabine and oxaliplatin or gemcitabine\u2009+\u2009cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. Eur J Cancer. 2019;123:162\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.004.","journal-title":"Eur J Cancer"},{"key":"16009_CR8","doi-asserted-by":"publisher","unstructured":"Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane database Syst Rev. 2018;4. https:\/\/doi.org\/10.1002\/14651858.CD011746.PUB2.","DOI":"10.1002\/14651858.CD011746.PUB2"},{"key":"16009_CR9","doi-asserted-by":"publisher","unstructured":"Lagenfelt H, Blomstrand H, Elander NO. Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/CANCERS13143507.","DOI":"10.3390\/CANCERS13143507"},{"key":"16009_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for prime time in biliary tract cancer. J Hepatol. 2020;73:170\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.007.","journal-title":"J Hepatol"},{"key":"16009_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMOA2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023;388:228\u201339. https:\/\/doi.org\/10.1056\/NEJMOA2206834.","journal-title":"N Engl J Med"},{"key":"16009_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"key":"16009_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/JAMAONCOL.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021;7:1669\u201377. https:\/\/doi.org\/10.1001\/JAMAONCOL.2021.3836.","journal-title":"JAMA Oncol"},{"key":"16009_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(20)30321-1.","journal-title":"Lancet Oncol"},{"key":"16009_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3.","journal-title":"Lancet Oncol"},{"key":"16009_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22:1290\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(21)00336-3.","journal-title":"Lancet Oncol"},{"key":"16009_CR17","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/jso.28081","volume":"131","author":"DI Tsilimigras","year":"2025","unstructured":"Tsilimigras DI, Stecko H, Moris D, Pawlik TM. Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co-Alterations and Outcomes. J Surg Oncol. 2025;131:1352\u201361. https:\/\/doi.org\/10.1002\/jso.28081.","journal-title":"J Surg Oncol"},{"key":"16009_CR18","doi-asserted-by":"publisher","unstructured":"Kalem A, Kus T, Gokcek S, Unek IT, Sahin TK, Dizdar O, et al. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG). J Clin Med. 2025;14. https:\/\/doi.org\/10.3390\/jcm14165868.","DOI":"10.3390\/jcm14165868"},{"key":"16009_CR19","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2217\/FON-2021-1302","volume":"18","author":"ZS Khankhel","year":"2022","unstructured":"Khankhel ZS, Goring S, Bobiak S, Lamy FX, Nayak D, Garside J, et al. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncol. 2022;18:2321\u201338. https:\/\/doi.org\/10.2217\/FON-2021-1302.","journal-title":"Future Oncol"},{"key":"16009_CR20","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1002\/CNCR.32463","volume":"125","author":"MA Lowery","year":"2019","unstructured":"Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, et al. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019;125:4426\u201334. https:\/\/doi.org\/10.1002\/CNCR.32463.","journal-title":"Cancer"},{"key":"16009_CR21","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1002\/CNCR.29471","volume":"121","author":"B Brieau","year":"2015","unstructured":"Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Ent\u00e9rologues Oncologues. Cancer. 2015;121:3290\u20137. https:\/\/doi.org\/10.1002\/CNCR.29471.","journal-title":"Cancer"},{"key":"16009_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Neoptolemos J, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol"},{"key":"16009_CR23","doi-asserted-by":"publisher","unstructured":"Leem G, Kim K, Kim J, Lee HS, Chung MJ, Park JY, et al. Comparison of second-line chemotherapy regimens in advanced biliary tract cancer: a systematic review, meta-analysis, and population-based cohort study. Int J Surg. 2026;112. https:\/\/doi.org\/10.1097\/js9.0000000000003367.","DOI":"10.1097\/js9.0000000000003367"},{"key":"16009_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","volume":"9","author":"J Hyung","year":"2023","unstructured":"Hyung J, Kim I, Kim KP, Ryoo BY, Jeong JH, Kang MJ, et al. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial. JAMA Oncol. 2023;9:692\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0016.","journal-title":"JAMA Oncol"},{"key":"16009_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/00365521.2019.1619827","volume":"54","author":"BG Song","year":"2019","unstructured":"Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, et al. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location. Scand J Gastroenterol. 2019;54:740\u20135. https:\/\/doi.org\/10.1080\/00365521.2019.1619827.","journal-title":"Scand J Gastroenterol"},{"key":"16009_CR26","doi-asserted-by":"publisher","unstructured":"Rizzo A, Salati M, Frega G, Merz V, Caputo F, Di Federico A, et al. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Med (Kaunas). 2022;58. https:\/\/doi.org\/10.3390\/MEDICINA58111543.","DOI":"10.3390\/MEDICINA58111543"},{"key":"16009_CR27","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/BJC.2014.190","volume":"110","author":"L Fornaro","year":"2014","unstructured":"Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165\u20139. https:\/\/doi.org\/10.1038\/BJC.2014.190.","journal-title":"Br J Cancer"},{"key":"16009_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, et al. Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014;3:1502. https:\/\/doi.org\/10.1002\/cam4.299.","journal-title":"Cancer Med"},{"key":"16009_CR29","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3109\/0284186X.2012.758872","volume":"52","author":"M Rand\u00e9n","year":"2013","unstructured":"Rand\u00e9n M, Helde-Frankling M, Runesdotter S, Strang P. Treatment decisions and discontinuation of palliative chemotherapy near the end-of-life, in relation to socioeconomic variables. Acta Oncol. 2013;52:1062\u20136. https:\/\/doi.org\/10.3109\/0284186X.2012.758872.","journal-title":"Acta Oncol"},{"key":"16009_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0825859720946505","volume":"36","author":"S Urvay","year":"2021","unstructured":"Urvay S, Civelek B, \u00d6zaslan E, S\u00fcrel AA. Chemotherapy at the End of Life. J Palliat Care. 2021;36:73\u20137. https:\/\/doi.org\/10.1177\/0825859720946505.","journal-title":"J Palliat Care"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16009-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:03:56Z","timestamp":1785517436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16009-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16009"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16009-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Table alignment has been fixed.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed according to the Helsinki declaration. Ethical approval was granted by the Regional Ethics Review board in Link\u00f6ping (diary number 2018\/139\u2009\u2212\u200931). Due to the retrospective non-interventional design and the fact that the majority of patients were not expected to be alive at time of data collection, the Ethics board waived the requirement for informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"496"}}